Tempus AI (NASDAQ:TEM) Downgraded by Wall Street Zen to Sell

Tempus AI (NASDAQ:TEM) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other brokerages also recently commented on TEM. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Guggenheim decreased their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $68.54.

Tempus AI Price Performance

Shares of TEM opened at $60.27 on Friday. The firm has a market capitalization of $10.82 billion, a P/E ratio of -35.04 and a beta of 3.46. Tempus AI has a 12-month low of $41.73 and a 12-month high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a fifty day moving average price of $50.48 and a 200-day moving average price of $54.57.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. Equities research analysts expect that Tempus AI will post -1.35 earnings per share for the current year.

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 11,529 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. The trade was a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 13,550 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the transaction, the chief executive officer owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 572,759 shares of company stock worth $29,238,424. 24.26% of the stock is owned by corporate insiders.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Aberdeen Group plc boosted its holdings in Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after acquiring an additional 102,878 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after acquiring an additional 36,096 shares during the last quarter. Bogart Wealth LLC increased its holdings in shares of Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares in the last quarter. Bamco Inc. NY increased its holdings in shares of Tempus AI by 53.7% during the third quarter. Bamco Inc. NY now owns 263,250 shares of the company’s stock valued at $21,247,000 after acquiring an additional 92,007 shares in the last quarter. Finally, Landscape Capital Management L.L.C. raised its position in shares of Tempus AI by 19.8% in the 3rd quarter. Landscape Capital Management L.L.C. now owns 136,372 shares of the company’s stock valued at $11,007,000 after purchasing an additional 22,581 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.